A Look at Hologic’s Gross Margin Trend

Hologic’s (HOLX) cost of product revenues increased from $881.8 million in fiscal 2017 to $886.6 million in fiscal 2018. Its amortization on intangible assets increased from $297.1 million in fiscal 2017 to $319.4 million in fiscal 2018 due to an increase associated with the Cynosure acquisition partially offset by lower amortization expenses related to the sale of its blood screening business. The company’s gross margin contracted from 64.07% in fiscal 2017 to 62.72% in fiscal 2018.